07:00 , Oct 3, 2011 |  BC Week In Review  |  Company News

Galena Biopharma cancer, dermatology news

RXi Pharmaceuticals Corp. changed its named to Galena Biopharma Inc. and said it will separate its cancer and RNAi assets into two public companies. The first - which will be named Galena - will develop...
00:26 , Sep 27, 2011 |  BC Extra  |  Company News

RXi to separate RNAi, cancer assets

RXi Pharmaceuticals Corp. (NASDAQ:RXII) said Monday it will separate its cancer and RNAi assets into two public companies. The first -- named Galena Biopharma Inc. -- will develop cancer vaccines, including NeuVax and a recently...
07:00 , Oct 4, 2010 |  BC Week In Review  |  Company News

EyeGate, RXi Pharmaceuticals deal

RXi partnered with EyeGate to develop RNAi therapeutics by combining RXi's self-delivering rxRNA compounds (sd-rxRNA) with EyeGate's EyeGate II ocular delivery system to treat retinal disorders. sd-rxRNAs use RNAi delivery technology from Advirna LLC (Boulder,...
07:00 , May 17, 2010 |  BC Week In Review  |  Clinical News

RXi Pharmaceuticals preclinical data

In mice, sd-rxRNA compounds displayed "robust" uptake in retinal cells and led to significant target gene silencing following local administration compared to conventional siRNA compounds. The self-delivering rxRNA compounds use RNAi delivery technology from Advirna...
07:00 , Apr 19, 2010 |  BC Week In Review  |  Company News

RXi Pharmaceuticals, TransDerm deal

The companies partnered to evaluate transdermal delivery of RXi's sd-rxRNA compounds using TransDerm's delivery technology to treat dermatological diseases, including pachyonychia congenita, a rare genetic skin disorder. Financial terms were not disclosed. The self-delivering rxRNA...
08:00 , Jan 25, 2010 |  BC Week In Review  |  Company News

RXi Pharmaceuticals, UMMS deal

RXi and the university will explore the application of RXi's sd-rxRNA compounds for ocular diseases such as age-related macular degeneration (AMD). The parties will use preclinical models of ocular disease to evaluate the delivery and...
07:00 , Oct 5, 2009 |  BC Week In Review  |  Company News

Advirna, RXi Pharmaceuticals deal

RXi acquired four of Advirna's RNAi delivery technologies for an undisclosed sum. RXi, which exercised an option to license the technologies in August, decided to purchase the technology based on preclinical results, including a mouse...
07:00 , Aug 10, 2009 |  BC Week In Review  |  Clinical News

RXi Pharmaceuticals preclinical data

In mice, RXi's sd-rxRNA compounds preferentially distributed to the liver and entered many cell types spontaneously. The self-delivering rxRNA compounds use RNAi delivery technology from Advirna LLC (Boulder, Colo.) (see BioCentury, Aug. 3). RXi Pharmaceuticals...
07:00 , Aug 3, 2009 |  BC Week In Review  |  Company News

Advirna LLC, RXi Pharmaceuticals deal

RXi exercised its option for exclusive, worldwide rights to four of Advirna's RNAi delivery technologies. RXi said its primary focus is on "self-delivery," which does not require a separate delivery vehicle for in vivo administration....